# Combination of Irinotecan and Temozolomide in Children With Brain Tumors.

> **NCT00404495** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 83 (actual)

## Conditions studied

- Glioma
- Medulloblastoma

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00404495
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2011-01
- **Final completion:** 2011-12
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2012-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00404495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00404495, "Combination of Irinotecan and Temozolomide in Children With Brain Tumors.". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00404495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*